Key features and details
- Sheep polyclonal to Von Willebrand Factor
- Reacts with: Mouse, Human
- Isotype: IgG
- Research with confidence – consistent and reproducible results with every batch
- Long-term and scalable supply – powered by recombinant technology for fast production
- Success from the first experiment – confirmed specificity through extensive validation
- Ethical standards compliant – production is animal-free
Product nameAnti-Von Willebrand Factor antibody
See all Von Willebrand Factor primary antibodies
DescriptionSheep polyclonal to Von Willebrand Factor
Species reactivityReacts with: Mouse, Human
Purified human von Willebrand factor.
General notesThis product should be stored undiluted. Storage in frost free freezers is not recommended. Should this product contain a precipitate we recommend microcentrifugation before use.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.40
Preservative: 0.09% Sodium azide
Constituents: Glycine buffered saline, 0.1% EACA, 0.01% Benzamidine, 0.0292% EDTA
Concentration information loading...
PurityIon Exchange Chromatography
Purification notesPurified IgG was prepared from serum by ion exchange chromatography.
FunctionImportant in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma.
Involvement in diseaseDefects in VWF are the cause of von Willebrand disease (VWD) [MIM:277480]. VWD defines a group of hemorrhagic disorders in which the von Willebrand factor is either quantitatively or qualitatively abnormal resulting in altered platelet function. Symptoms vary depending on severity and disease type but may include prolonged bleeding time, deficiency of factor VIII and impaired platelet adhesion. Type I von Willebrand disease is the most common form and is characterized by partial quantitative plasmatic deficiency of an otherwise structurally and functionally normal Willebrand factor; type II is associated with a qualitative deficiency and functional anomalies of the Willebrand factor; type III is the most severe form and is characterized by total or near-total absence of Willebrand factor in the plasma and cellular compartments, also leading to a profound deficiency of plasmatic factor VIII.
Sequence similaritiesContains 1 CTCK (C-terminal cystine knot-like) domain.
Contains 4 TIL (trypsin inhibitory-like) domains.
Contains 3 VWFA domains.
Contains 3 VWFC domains.
Contains 4 VWFD domains.
DomainThe von Willebrand antigen 2 is required for multimerization of vWF and for its targeting to storage granules.
modificationsAll cysteine residues are involved in intrachain or interchain disulfide bonds.
N- and O-glycosylated.
Cellular localizationSecreted. Secreted > extracellular space > extracellular matrix. Localized to storage granules.
- Information by UniProt
- Coagulation factor VIII antibody
- Coagulation factor VIII VWF antibody
- F8VWF antibody
ab11713 has been referenced in 69 publications.
- Liu S et al. Reduced patency in left-sided arteriovenous grafts in a porcine model. J Vasc Surg 72:305-317.e6 (2020). PubMed: 31699515
- Hou Z et al. Lactic acid-mediated endothelial to mesenchymal transition through TGF-ß1 contributes to in-stent stenosis in poly-L-lactic acid stent. Int J Biol Macromol 155:1589-1598 (2020). PubMed: 31770555
- Hu H et al. TGFß (Transforming Growth Factor-Beta)-Activated Kinase 1 Regulates Arteriovenous Fistula Maturation. Arterioscler Thromb Vasc Biol 40:e203-e213 (2020). PubMed: 32460580
- Gaddam RR et al. Microbiota-governed microRNA-204 impairs endothelial function and blood pressure decline during inactivity in db/db mice. Sci Rep 10:10065 (2020). PubMed: 32572127
- Tilburg J et al. SLC44A2 deficient mice have a reduced response in stenosis but not in hypercoagulability driven venous thrombosis. J Thromb Haemost 18:1714-1727 (2020). PubMed: 32297475
Customer reviews and Q&As
Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact email@example.com